← All episodes

Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN

| 7 products mentioned
TBPN TBPN host
Watch on YouTube ai adoption in pharma biotech acquisitions frontier ai models ai infrastructure bottlenecks antitrust and ai regulation drug development acceleration ai pricing and compute costs

This episode covers major developments in AI and biotech, including Novartis' $2 billion acquisition of Excellergy, a stealth-mode allergy drug company, and Anthropic's new Mythos model which represents a significant leap in AI capabilities. The hosts discuss how AI is being practically applied in pharmaceutical workflows, the competitive landscape of frontier AI models, and Anthropic's legal victory against Pentagon supply chain restrictions.

Key takeaways
  • • AI in pharma isn't about curing cancer directly—it's about automating tedious documentation tasks like FDA filings, allowing companies to submit applications faster and run more trial variations.
  • • Excellergy's $2B exit in five years demonstrates strong biotech fundamentals: academic research → VC backing → specialist capital → CEO with successful track record (Todd Zavodinik has now orchestrated three billion-dollar exits).
  • • Anthropic's Mythos model shows dramatically higher performance in coding, reasoning, and cybersecurity, with pricing around 10x higher than current Claude models, reflecting compute scarcity and companies' willingness to pay for capabilities.
  • • Claude's usage limits during peak hours have driven users toward polyphasic sleep schedules or geographically distributed teams to work around rate restrictions, signaling demand far outstrips supply.
  • • Anthropic won a major legal victory with the court finding the Pentagon's supply chain risk designation likely unconstitutional, enabling the company to focus on the AI race rather than regulatory battles.
  • • Apple is opening Siri to rival AI assistants like ChatGPT and Gemini via app store integration, partly as an antitrust concession but also to monetize third-party AI subscriptions.

Recommendations (5)

Python
Python uses

"We actually wrote Python scripts to programmatically interact with the word documents"

TBPN · ▶ 2:34

ARC-AGI
ARC-AGI recommends

"I still love the benchmark and the team over at ARC for what they're doing"

TBPN · ▶ 9:58

Claude
Claude uses

"To manage growing demand for Claude, we're adjusting our five hour session limits"

TBPN · ▶ 14:12

ChatGPT
ChatGPT uses

"I did it. ChatGPT is like I don't use it like I use Google"

TBPN · ▶ 25:24

Safari
Safari uses

"When you go to the Safari search bar and you just type in some random words, it searches Google"

TBPN · ▶ 25:15

Mentioned (2)

Zolair "The current blockbuster drug in the category is called Zolair" ▶ 3:52
Cursor
Cursor "They're paying more cursor" ▶ 12:02

More from these creators

Is Meta Really Addictive?, Jetsons Prediction, Artemis II: Back to the Moon | Diet TBPN

TBPN · Mar 31, 2026 · 2 recs

FULL INTERVIEW: Why I Think Nvidia Is Perfectly Positioned In The AI Race

TBPN · Mar 30, 2026 · 4 recs

TBPN Gets Addicted to Social Media, Japan Twitter, Warren Buffett's Protégé, Deals Deals Deals

TBPN · Mar 30, 2026 · 6 recs

The $6M Verdict That Could Kill Social Media

TBPN · Mar 30, 2026

How I Built and Sold SALT & STONE

TBPN · Mar 27, 2026 · 6 recs

Arm’s $15B Chip Bet, Sanders & AOC vs Datacenters, Meta & YouTube Lose Trial | Diet TBPN

TBPN · Mar 27, 2026